Special Drug Use Surveillance of Irribow in Female Patients

• Status: Completed
• Trial end date: 2018-03-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Ramosetron

Criteria

Inclusion Criteria:

• Female patients with diarrhea-predominant irritable bowel syndrome

Exclusion Criteria:

-